MedTrace Logo

Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism

NCT00307840 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2006-03-28

No results posted yet for this study

Summary

The purpose of this study was to compare two different initial dosing schemes for the administration of paricalcitol in hemodialysis patients with secondary hyperparathyroidism: the already in use iPTH/80 scheme, and an iPTH/120 scheme, which corresponds to the immediately lower dose, based on current instructions on paricalcitol dose adjustment. We studied the effectiveness of the two dosing schemes in achieving a target iPTH level (150 - 300 pg/mL)

Conditions

  • Secondary Hyperparathyroidism

Interventions

DRUG

paricalcitol

Sponsors & Collaborators

  • Papageorgiou General Hospital

    lead OTHER

Principal Investigators

  • Efstathios Mitsopoulos, MD · Papageorgiou General Hospital, Thessaloniki, Greece

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Completion
2005-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00307840 on ClinicalTrials.gov